Sidley Advises CanSino Biologics Inc.’s HK$1.25 Billion H-Share Listing
Sidley advised CanSino Biologics Inc. (HKEX: 6185) as the Hong Kong and U.S. counsel in its HK$1.25 billion (approximately US$160.5 million) global offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong Limited. Morgan Stanley Asia Limited and CLSA Capital Markets Limited acted as joint sponsors in this transaction.
CanSino Biologics Inc. is a bio-tech leader in research and development, manufacturing and commercialization of vaccine products for human use in China.